00:55 , Mar 16, 2018 |  BioCentury  |  Emerging Company Profile

Cirius safety

Cirius Therapeutics Inc. is developing a second-generation insulin sensitizer for non-alcoholic steatohepatitis that is designed to avoid cardiovascular symptoms and edema associated with first-generation agents. Insulin-sensitizing thiazolidinediones (TZDs) including Actos pioglitazone from Takeda Pharmaceutical Co. Ltd....
18:50 , Mar 15, 2018 |  BC Innovations  |  Emerging Company Profile

Stabilizing damaged goods

Methuselah Health Inc. aims to treat aging-related diseases by stabilizing proteins that have adopted dysfunctional conformations as a result of genomic or environmental damage. By studying damaged proteins instead of DNA, the newco can find...
20:37 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Takeda, Zinfandel's AD test fails to deliver

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMMORROW trial of 0.8 mg pioglitazone (AD-4833) after a planned interim futility analysis showed that the compound was inadequate...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
22:51 , Jan 25, 2018 |  BC Extra  |  Clinical News

Takeda, Zinfandel’s AD test fails to deliver

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMORROW trial of 0.8 mg pioglitazone (AD-4833) SR after an interim futility analysis showed the compound was inadequate in...
21:52 , Oct 5, 2017 |  BC Innovations  |  Strategy

Fixing FDA’s FAERS

Last week FDA announced a new searchable format for its adverse events reporting database, making it easier for drug developers to use the tool to de-risk drug candidates. But according to an August publication...
18:11 , Jun 1, 2017 |  BC Extra  |  Company News

Strekin raises CHF10 million

Strekin AG (Basel, Switzerland) raised CHF10 million ($10.3 million) in its third seed round from undisclosed private investors. The round builds on a combined CHF8.2 million ($8.4 million) Strekin had raised in seed rounds during...
20:04 , Apr 14, 2017 |  BioCentury  |  Finance

More NASH cash

Investors are hoping a $40 million A-2 round can help Cirius Therapeutics Inc. deliver the first clinical data in non-alcoholic steatohepatitis (NASH) showing a second-generation insulin sensitizer is not only efficacious, but also avoids the...
13:46 , Apr 11, 2017 |  BC Extra  |  Financial News

NASH newco Cirius raises $40M in series A

Liver company Cirius Therapeutics Inc. (Kalamazoo, Mich.) raised $40 million in a series A round led by Frazier Healthcare Partners and Novo A/S (Hellerup, Denmark). New investors Adams Street Partners and Renaissance Venture Capital Fund...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

DRX-065: Phase Ia started

DeuteRx began an open-label, U.S. Phase Ia trial to compare 22.5 mg DRX-065 vs. 45 mg Actos pioglitazone in up to 12 healthy adult volunteers. Pending data from the 2 cohorts, a third cohort...